Karuna Therapeutics Announces KarXT Met Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Karuna Therapeutics Inc. (KRTX) Climbs 30%
November 19, 2019 10:36 AM ESTKaruna Therapeutics Inc. (NASDAQ: KRTX) Climbs 30%
... MoreKaruna Therapeutics Inc. (KRTX) Halted on LUDP
November 19, 2019 10:18 AM ESTKaruna Therapeutics Inc. (NASDAQ: KRTX) Halted on LUDP
... MoreKaruna Therapeutics Inc. (KRTX) Confirms Proposed 2.6M Share Public Offering of Common Stock
November 18, 2019 4:22 PM ESTKaruna Therapeutics, Inc. (Nasdaq: KRTX), a clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders and pain, today announced that it has commenced an underwritten public offering of 2,600,000... More
Karuna Therapeutics Inc. (KRTX) Halted on LUDP, Up 230%
November 18, 2019 9:53 AM ESTKaruna Therapeutics Inc. (NASDAQ: KRTX) Halted on LUDP, Up 230%
... MoreKaruna Therapeutics Inc. (KRTX) Extends Gain, Up 175%
November 18, 2019 9:47 AM ESTKaruna Therapeutics Inc. (NASDAQ: KRTX) Extends Gain, Up 175%
... MoreKaruna Therapeutics Inc. (KRTX) Climbs 58% After KarXT Meets Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia
November 18, 2019 7:17 AM ESTKaruna Therapeutics (NASDAQ: KRTX) Climbs 58% After KarXT Meets Primary Endpoint in Phase 2 Clinical Trial of Acute Psychosis in Patients with Schizophrenia
... More